Andrew Guggenhime Sells 8,000 Shares of Vaxcyte, Inc (NASDAQ:PCVX) Stock theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
The global PCV market, valued at ~$8 billion annually, is poised for significant growth, estimated to reach ~$12 billion soon. Market dynamics are shifting towards adults, potentially doubling with the US discussing vaccination age reduction. Prevnar20 dominates with 97% market share in adults, but Vaxcyte's advanced conjugate capabilities present a competitive advantage.
The global market study pneumococcal conjugate (PCV) market is ~$8 billion per year, and Vaxcyte Inc PCVX estimates it will grow to ~$12 billion in the next…
Avalon GloboCare (NASDAQ:ALBT – Get Free Report) and Vaxcyte (NASDAQ:PCVX – Get Free Report) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, risk, profitability and valuation. Volatility & Risk Avalon GloboCare has a beta of […]